SynthesisDisease markers2015
Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review.
Synthesis in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- TRAF6 as a potential target in advanced breast cancer: a systematic review, meta-analysis, and bioinformatics validation.Scientific reports · 2023Pooled it
- Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.Frontiers in oncology · 2020Pooled it
- Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence.Frontiers in oncology · 2019Pooled it
- Prognostic and clinicopathological value of FoxM1 expression in colorectal cancer: A systematic review and meta-analysis.Medicine · 2018Pooled it
- MicroRNA-532-3p Modulates Colorectal Cancer Cell Proliferation and Invasion via Suppression of FOXM1.Cancers · 2024Article
- Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.World journal of surgical oncology · 2023Article
- A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics.Annals of translational medicine · 2021Review
- FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.Cancers · 2021Review
- Co-regulation and function ofeLife · 2021Article
- The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer.Molecules (Basel, Switzerland) · 2021Review
- Article
- Prognostic and Predictive Value of Transcription Factors Panel for Digestive System Carcinoma.Frontiers in oncology · 2021Article
- Expression, association with clinicopathological features and prognostic potential of CEP55, p-Akt, FoxM1 and MMP-2 in astrocytoma.Oncology letters · 2020Article
- Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.Oncology reports · 2020Article
- The DNMT1/miR-34a/FOXM1 Axis Contributes to Stemness of Liver Cancer Cells.Journal of oncology · 2020Article
- FOXM1 functions collaboratively with PLAU to promote gastric cancer progression.Journal of Cancer · 2020Article
- Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.BMC cancer · 2019Article
- Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.Cancer medicine · 2019Article
- A Diagnostic Tool for Identification of Etiologies of Fever of Unknown Origin in Adult Patients.Current medical science · 2019Article
- Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.Molecular oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forkhead box M1 (FOXM1), a member of the Fox transcription factors family, was closely related with cell cycle. FOXM1 played an important role in MST and prompted a poor prognosis for MST patients. However, there were also some studies revealing no significant association between the FOXM1 expression and prognosis of patients. Therefore, we conducted meta-analysis to investigate whether the expression of FOXM1 was associated with MST prognosis. We collected 36 relevant studies through PubMed database and obtained research data of 4946 patients. Stata 12.0 was used to express the results as hazard ratio (HR) for time-to-event outcomes with 95% confidence intervals (95% CI). It was shown that overexpression of FOXM1 was relevant to worse survival of MST patients (HR = 1.99, 95% CI = 1.79-2.21, P < 0.001; I(2) = 26.4%, P h = 0.076). Subgroup analysis suggested that overexpression of FOXM1 in breast cancer (BC), gastric cancer (GC), hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDA), and non-small-cell lung cancer (NSCLC) all predicted a worse survival (P < 0.05), in addition to ovarian cancer (OC) (P = 0.084). In conclusion, our research indicated that overexpression of FOXM1 was to the disadvantage of the prognosis for majority of MST and therefore can be used as an evaluation index of prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.